944808-08-6

Usage

Uses

Used in Pharmaceutical Industry:
Tert-Butyl-4-(2-fluorophenoxy)piperidine-1-carboxylate is used as a building block or intermediate for the synthesis of various biologically active compounds. Its unique structure and functional groups contribute to the development of new drugs with potential therapeutic applications.
Used in Organic Chemistry:
In the field of organic chemistry, Tert-Butyl-4-(2-fluorophenoxy)piperidine-1-carboxylate serves as a versatile intermediate for the synthesis of a wide range of organic compounds. Its reactivity and structural features make it a valuable component in the preparation of complex organic molecules and materials.
Used in Drug Design and Development:
Tert-Butyl-4-(2-fluorophenoxy)piperidine-1-carboxylate is employed as a key component in drug design and development. Its unique structure allows for the creation of novel drug candidates with improved pharmacological properties, such as enhanced stability, bioavailability, and target selectivity.
Used in Medicinal Chemistry Research:
In medicinal chemistry research, Tert-Butyl-4-(2-fluorophenoxy)piperidine-1-carboxylate is utilized as a starting material or scaffold for the exploration of new chemical entities with potential therapeutic benefits. Its structural diversity and modifiable functional groups enable the design of innovative compounds with optimized pharmacological profiles.
Overall, Tert-Butyl-4-(2-fluorophenoxy)piperidine-1-carboxylate is a valuable chemical compound with diverse applications in various industries, particularly in the development of new drugs and organic compounds with potential therapeutic and practical applications.

Upstream product

• 367-12-4 2-fluorophenol 
• 109384-19-2 t-butyl 4-hydroxy piperidine-1-carboxylate 

Downstream Products

• 3413-29-4 4-(2-fluorophenoxy)piperidine hydrochloride 
• 3623-02-7 4-(2-fluorophenoxy)piperidine 

Relevant academic research and scientific papers

Identification of a new series of benzothiazinone derivatives with excellent antitubercular activity and improved pharmacokinetic profiles

Nitrobenzothiazinone (BTZ) is a promising scaffold with potent activity against M. tuberculosis by inhibiting decaprenylphosphoryl-beta-d-ribose 2′-oxidase (DprE1). But unfavorable durability poses a challenge to further development of this class of agents. Herein, a series of BTZs bearing a variety of different substituents at the C-2 position were designed and synthesized. Compounds were screened for their antimycobacterial activity against Mycobacterium tuberculosis H37Ra and were profiled for metabolic stability, plasma protein-binding capacity and pharmacokinetics in vivo. In general, these new BTZs containing N-piperazine, N-piperidine or N-piperidone moiety have excellent antitubercular activity and low cytotoxicity. Several of the compounds showed improved microsomal stability and lower plasma protein-binding, opening a new direction for further lead optimization. And we obtained compound 3o, which maintained good anti-tuberculosis activity (MIC = 8 nM) and presented better in vitro ADME/T and in vivo pharmacokinetic profiles than reported BTZ compound PBTZ169, which may serve as a candidate for the treatment of tuberculosis.

Benzothiazine derivative, a preparation method and uses thereof

The invention belongs to the field of chemical medicine, particularly relates to a benzothiazine derivative, a preparation method and uses thereof, and provides a benzothiazine derivative, a preparation method and uses thereof, wherein the structure is represented by a formula I. The invention further provides a preparation method and uses of the benzothiazine derivative. The formula I is definedin the specification.

ACETYLENE DERIVATIVES AS STEAROYL COA DESATURASE INHIBITORS

The present invention provides Stearoyl CoA Desaturase (SCD) inhibitors, hi particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by Stearoyl CoA Desaturase 1 (SCD 1) inhibitors. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by Stearoyl CoA Desaturase (SCD) inhibitors.

Discovery of piperidine-aryl urea-based stearoyl-CoA desaturase 1 inhibitors

A series of structurally novel stearoyl-CoA desaturase1 (SCD1) inhibitors has been identified via molecular scaffold manipulation. Preliminary structure-activity relationship (SAR) studies led to the discovery of potent, and orally bioavailable piperidine-aryl urea-based SCD1 inhibitors. 4-(2-Chlorophenoxy)-N-[3-(methyl carbamoyl)phenyl]piperidine-1-carboxamide 4c exhibited robust in vivo activity with dose-dependent desaturation index lowering effects.

Discovery of potent, selective, orally bioavailable stearoyl-CoA desaturase 1 inhibitors

Stearoyl-CoA desaturase 1 (SCD1) catalyzes the committed step in the biosynthesis of monounsaturated fatty acids from saturated, long-chain fatty acids. Studies with SCD1 knockout mice have established that these animals are lean and protected from leptin